β-blockers in Heart Failure

Carvedilol was studied in patients with NYHA class II and III HF (U.S. Carvedilol Heart Failure Study),12 as well as in patients with more severe HF as in the Carvedilol Prospective Randomized Cumulative Survival Study (COPERNICUS).13 After a median of 6.5 months, the primary endpoint of death was reported in 3.2% of patients in the U.S ... ................
................